Allogene Therapeutics, Inc. Income Statement

1Y3Y5Y7Y10YAll
Download Data
Income Statement Dec2018 Dec2019 Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Revenue & cost
Revenue -3.36M114.09M0.16M0.10M0.02M
Gross Profit -3.36M114.09M0.16M0.10M0.02M
Operating items
Research & Development 151.86M144.53M192.99M220.18M256.39M242.91M192.30M
Selling, General & Administrative 40.98M57.47M65.26M74.11M79.31M71.67M65.20M
Other Operating Expenses 13.24M15.72M
Operating Expenses 192.84M202.01M258.24M294.28M335.69M327.83M273.22M
Operating Income -192.84M-202.01M-258.24M-180.19M-335.54M-327.74M-273.20M
EBIT -192.84M-202.01M-258.24M-180.19M-335.54M-327.74M-273.20M
Non-operating items
Interest & Investment Income 9.16M1.71M4.57M18.31M20.15M
Other Non Operating Income 5.79M17.35M-67.30M-3.57M-9.44M-17.84M-3.92M
Non Operating Income -18.78M17.35M-67.30M-3.57M-9.44M-17.84M16.05M
Net income details
EBT -211.62M-184.93M-250.22M-257.00M-330.97M-327.26M-257.15M
Tax Provisions -0.12M-0.33M0.44M
Profit After Tax -211.50M-184.59M-316.38M-182.05M-340.41M-327.26M-257.59M
Income from Continuing Operations -211.50M-184.59M-250.22M-257.00M-330.97M-327.26M-257.59M
Consolidated Net Income -211.50M-184.59M-250.22M-257.00M-330.97M-327.26M-257.59M
Income towards Parent Company -211.50M-184.59M-250.22M-257.00M-330.97M-327.26M-257.59M
Net Income towards Common Stockholders -211.50M-184.59M-250.22M-257.00M-330.97M-327.26M-257.59M
Additional items
EPS (Basic) -0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M
EPS (Weighted Average and Diluted) -0.00M-0.00M-0.00M-0.00M-0.00M-0.00M
Shares Outstanding (Weighted Average) 121.48M121.90M140.65M142.52M144.21M168.28M209.67M
Shares Outstanding (Diluted Average) 101.06M120.37M135.82M143.15M156.93M194.81M
EBITDA -211.20M-183.75M-317.26M-184.89M-347.77M-318.29M-256.72M
Tax Rate 0.00M0.00M